Scientific Program Committee

Poster Litings
Session 60 CROI 2008
329 Antiviral Efficacy of a CTL Immune Response Focused on
Conserved HIV-1 Segments
Morgane Rolland* 1 , W Deng1 , C Rousseau1 , H Coovadia2 , K Bishop2 ,
P Goulder3,4 , B Walker2,3 , C Brander3 , and J Mullins1 1 2 Univ of Washington, Seattle, US; Doris Duke Med Res Inst, Univ
of KwaZulu Natal, Durban, South Africa; 3Partners AIDS Res Ctr,
Massachusetts Gen Hosp, Harvard Med Sch, Charlestown, US; and 4Univ of Oxford, UK
330 Discordant Neutralization of HIV by CTL Targeting Core
and Envelope Proteins
Huabiao Chen* 1,2 , A Trocha1,2 , F Pereyra1 , T Miura1,2 , M Brockman1,2 ,
B Julg1 , B Baker1 , A Rothchild1 , B Block1 , and B Walker1,2 1 2 Massachusetts Gen Hosp, Harvard Med Sch, Boston, US and Howard
Hughes Med Inst, Chevy Chase, MD, US
331 Antigenic Escape of SIVmac239 in a SIVmac239-Infected Rhesus
Macaque in vivo with an Unusually High-titer Neutralizing
Antibody Response
Shuji Sato*, E Yuste, H Sanford, A Lauer, E Chang, R Desrosiers, and
W Johnson
New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US
332 Viral Escape from a Novel HLA-C0102-restricted
Immunodominant Gag CTL Epitope in HIV-1 Subtype
CRF01_AE-infected Thai Patients
Supranee Buranapraditkun* 1 , P Chatkulkawin1 , R Allgaier2 ,
SI Lorenzen1 , P Thantiworasit1 , P Pitakpolrat1 , S Sirivichayakul1 ,
B Walker2 , T Allen2 , and K Ruxrungtham1 1 2 Chulalongkorn Univ, Bangkok, Thailand and Partners AIDS Res Ctr,
Boston, MA, US
333 HIV-1 Escape Driven by HLA-B*13 CD8 T Cell Responses
Targeting p15 Gag Is Associated with Fitness Cost and
Modification of the Gag-Pol Frameshift Stem-loop
Julia Prado*, I Honeyborne, and P Goulder
Univ of Oxford, UK
334 HLA-B Alleles Selecting Multiple Escape Mutations in Gag
Are Associated with Reduced Viremia
Philippa Matthews* 1 , A Prendergast1 , A Leslie1 , R Payne1 ,
H Crawford1 , C Rousseau2 , T Ndung’u3 , B Walker3,4 , D Heckerman5 , and
P Goulder1,3,4 1 2 3 Univ of Oxford, UK; Univ of Washington, Seattle, US; Univ of KwaZulu
Natal, Durban, South Africa; 4Harvard Univ, Boston, MA, US; and
5Microsoft Res, Redmond, WA, US
335 Accumulation of CTL Escape Variants and HLA-driven
Convergence of Viral Subtypes
Dario Alberto Dilernia* 1 , L Lourtau2 , L Jones1,3 , G Turk1 ,
M Gomez-Carrillo1 , C Bautista4 , J Benetucci5 , M Losso2 , P Cahn6 , and
H Salomon1 1 2 Argentinean Reference Ctr for AIDS, Buenos Aires; Hosp Gen de
Agudos “Jose Maria Ramos Mejia”, Buenos Aires, Argentina; 3Estacion de Fotobiologia Playa Union, Buenos Aires, Argentina; 4Assn Benefica
PRISMA, Lima, Peru; 5Hosp de Enfermedades Infecciosas “Francisco
J Muniz”, Buenos Aires, Argentina; and 6Hosp Gen de Agudos “Juan A
Fernandez”, Buenos Aires, Argentina
b Tuesday, 1-4 pm; Hall D
Session 61–Poster Abstracts
Factors Influencing CD4 Counts
336 CD4 Loss Rate in Untreated Chronic HIV-1 Infection May
Be Better Predicted by PD-1 than HIV RNA and CD38
M Holm, F Pettersen, and Dag Kvale*
Ulleval Univ Hosp, Univ of Oslo, Norway
337 Maintenance of Proliferative PD-1 low Memory CD8 + T Cells
Specific for Eradicated Virus in HIV-1 Patients with High
CD4 Count
Ai Kawana-Tachikawa*, M Motose, T Odawara, T Fuji, and A Iwamoto
Inst of Med Sci, Univ of Tokyo, Japan
338 Decline in Regulatory T Cells Is Associated with Generalized
Immune Activation during HIV Disease Progression
Andrew Prendergast*, P Klenerman, and P Goulder
Univ of Oxford, UK
339 Differential Expression of Genes Associated with Apoptosis
Predicts CD4 Decline after Interruption of ART in ACTG
A5170
Maryanne Vahey* 1 , Z Wang2 , Z Su3 , A Krambrink3 , D Skiest4 , and
D Margolis5 1 2 Walter Reed Army Inst of Res, Washington, DC, US; Henry M Jackson
Fndn, Rockville, MD, US; 3Harvard Sch of Publ Hlth, Boston, MA, US;
4 5 Baystate Med Ctr, Springfield, MA, US; and Univ of North Carolina at
Chapel Hill, US
340 Plasma IL-7 Levels Do Not Evolve in Parallel to CD4 + Counts
at Early Stages of HIV Infection
Jose Benito*, M Lopez, S Lozano, J Gonzalez-Lahoz, and V Soriano
Hosp Carlos III, Madrid, Spain
30 15th Conference on Retroviruses and Opportunistic Infections
341 HIV-1 Proviral Hypermutation Associates with Decline in
CD4 Count in HIV-infected Kenyan Women
Allison Land* 1 , B Ball1 , M Luo1 , R Pilon2 , P Sandstrom2 , J Embree1 ,
C Wachihi3 , J Kimani3 , and F Plummer1,4 1 2 Univ of Manitoba, Winnipeg, Canada; Publ Hlth Agency of Canada,
Ottawa; 3Univ of Nairobi, Kenya; and 4Publ Hlth Agency of Canada,
Winnipeg
342 Non-invasive in vivo Imaging of CD4 Cells in SHIV-infected
Rhesus Monkeys
Michele Di Mascio* 1 , C Paik2 , J Carrasquillo3 , JS Maeng2 , S Srinivasula4 ,
M Catalfamo1 , Y Nishimura1 , K Reimann5 , M Martin1 , and C Lane1 1 2 NIAID, NIH, Bethesda, MD, US; Warren G Magnuson Clinical Ctr,
NIH, Bethesda, MD, US; 3Memorial Sloan Kettering Cancer Ctr, New
York, NY, US; 4SAIC-Frederick, MD, US; and 5Beth Israel Deaconess
Med Ctr, Boston, MA, US
343 The Frequency and Clinical Implications of a Discordant
CD4 Count and CD4 Percentage
M Gompels1 , Caroline Sabin* 2 , A Phillips2 , D Dunn3 , and the UK
Collaborative HIV Cohort (CHIC) Study
1 2 North Bristol NHS Trust, UK; Royal Free and Univ Coll Med Sch,
London, UK; and 3Med Res Council Clinical Trials Unit, London, UK
b Tuesday, 1-4 pm; Hall D
Session 62–Poster Abstracts
HIV Superinfection and Viral Co-infection
344 Transmission of HIV-1 in Seroconcordant Couples
Mary Campbell* 1 , G Gottlieb1 , K Wong1 , S Hawes1 , T Lampinen2 ,
N Kiviat1 , and J Mullins1 1 2 Univ of Washington, Seattle, US and Univ of British Columbia,
Vancouver, Canada
345 Estimate of the Frequency of HIV-1 Co-infection in vivo
Igor Rouzine* 1 , E Gubankova1 , M Kearney2 , S Palmer2 , F Maldarelli2 , and
J Coffin1 1 2 Tufts Univ, Boston, MA, US and HIV Drug Resistance Prgm, NCI-
Frederick, MD, US
346 Down Regulation of β-Chemokines Production in Human T
Cell Leukemia/Lymphoma Virus Type 2 Subtype 2a-infected
Subjects, Regardless of HIV-1 or HCV Infections
I Olah1 , A Brito1 , L Fukumori1 , J Smid2 , A Oliveira2 , A Duarte1 , and
Jorge Casseb* 1,2
1 2 Sao Paulo Univ, Sch of Med, Brazil and Inst of Infectious Diseases, Sao
Paulo, Brazil
b Wednesday, 1-4 pm; Hall D
Session 63–Poster Abstracts
Studies on Elite Controllers and Exposed Uninfected
347 Longitudinal Measurements of Ultra-sensitive Plasma HIV
RNA and Quantitative Antibody Levels in HIV-1-infected
Individuals Who Naturally Maintain Viral Loads below the
Limit of Conventional Detection
Hiroyu Hatano* 1 , E Delwart1,2 , P Norris1,2 , R Hoh1 , M Busch1,2 , J Martin1 ,
and S Deeks1 1 2 Univ of California, San Francisco, US and Blood Systems Res Inst, San
Francisco, CA, US
348 Low-level Virema in HIV-1-infected Patients Classified as
Elite Controllers Compared to Patients on Suppressive ART
Sarah Palmer* 1 , A Wiegand1 , T Miura2 , B Block2 , F Pereyra2 ,
F Maldarelli1 , J Mellors3 , B Walker2 , and J Coffin4 1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US; Partners AIDS
Res Ctr, Massachusetts Gen Hosp, Boston, US; 3Univ of Pittsburgh, PA,
US; and 4Tufts Univ, Boston, MA, US
349 Ongoing Low-level Viral Replication and Polyfunctional CD8
T Cell Responses Detected in the HIV Elite Controllers
Florencia Pereyra* 1 , T Miura1 , S Palmer2 , B Block1 , A Rothchild1 ,
B Baker1 , J Coffin2 , and B Walker1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Charlestown and
Harvard Med Sch, Boston, US and 2NCI-Frederick, MD, US
350 Viral Dynamics of Elite Suppressors in HIV-1 Infection
Jason Dinoso* 1 , S Kim1 , J Blankson1 , and R Siliciano1,2 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Howard
Hughes Med Inst, Baltimore, MD, US
351 Is There a Harmless Level of Plasma Viremia in Untreated
HIV Infection? CD4 + T Cells in the Long-term Follow-up of
Elite Controllers and Controls
Hans-Jurgen Stellbrink* 1 , K Schewe1 , C Hoffmann1 , and E Wolf2 1 2 IPM Study Ctr, Hamburg, Germany and MUC Res, Munich, Germany
352 HIV-1 Proviral Load in Elite Suppressors with Low or
Declining CD4 Counts
J Deayton1,2 , Katherine Groves* 1 , D Bibby2 , H Dreja1 , K Aubin1 ,
C DeSouza2 , J Hand2 , D Clark2 , C Orkin2 , and A McKnight1 1 2 Queen Mary Sch of Med and Dentistry, London, UK and Barts and the
London NHS Trust, UK